Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

This study is ongoing, but not recruiting participants.
Celgene Corporation
Roche Pharma AG
Information provided by (Responsible Party):
German Breast Group Identifier:
First received: April 18, 2012
Last updated: October 11, 2016
Last verified: October 2016